Vivani Targets August 2026 for First SLIM-1 Dosing, Advancing Its Obesity Implant
VANI sits 55% above its 52-week low of $0.923.
Summary
Vivani Medical expects to dose the first patient in its SLIM-1 Phase 1 trial of the NPM-139 semaglutide implant in August 2026, a key step toward addressing adherence and convenience challenges in the obesity market.
Key Events · Product Development and Regulatory · VANI
-
SLIM-1 Dosing Set for August 2026
First patient dosing in the Phase 1 SLIM-1 trial of NPM-139 (semaglutide implant) is projected for August 2026, following HREC approval in Australia in June 2026.
-
Clinical Momentum Builds
The update follows positive first-in-human LIBERATE-1 results and a recent agreement with Novo Nordisk to evaluate the implant, underscoring growing industry interest.
-
Differentiated Obesity Pipeline
NPM-139 is the only subdermal GLP-1 implant in clinical development for obesity, designed for once- or twice-yearly dosing to guarantee adherence and improve outcomes.
-
Cash Runway Through Key Milestones
The company reiterated that its cash runway is expected to fund the current plan, including completion of the NPM-139 clinical program initiation, through the first half of 2027.
Analysis · VANI · Industrial Applications And Services
Vivani Medical disclosed that first dosing in its SLIM-1 Phase 1 trial for the NPM-139 semaglutide implant is expected in August 2026. This marks a concrete near-term milestone for the lead obesity program, coming just weeks after Novo Nordisk agreed to evaluate the technology. The update reinforces the company's clinical momentum and positions the implant as a differentiated, long-acting GLP-1 option in a market projected to reach $190 billion by 2035.
At the time of this filing, VANI was trading at $1.43 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $121.6M. The 52-week trading range was $0.92 to $1.92. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.